The market for blood screening was valued at US$ 2.3 billion in 2021 and is anticipated to grow at a CAGR of 7.7% from 2023 to 2032.
Growing awareness regarding blood donation, increasing requirement of healthy blood form clinical applications, prevalence of infectious diseases, rising number of surgical procedures, and stringent regulations to monitor blood quality are the primary forces shaping the global blood screening market. Advancement in clinical research has helped in identifying new pathogens responsible for infectious diseases, which is expected to contribute towards the growth of blood screening market in coming years.
The awareness regarding blood donation is spreading in the mid-income and low-income countries owing to the government offered incentives for blood donation. This has increased the volume of donated blood and has in turn encouraged the adoption of blood screening process to ensure the absence of infection markers.
Increase in the volume of surgeries has resulted in high demand for healthy blood to cope up with blood loss during the surgical procedures. This has fueled the demand for efficient blood screening methods. Consequently, the global blood screening market is expected to witness prominent growth during the forecast period.
North America contributed the largest share to the global blood screening market in 2019 and is expected to witness prominent growth during the forecast period. Prevalence of infectious diseases, rising demand for healthy blood, and growth in volume of donated blood are the key factors contributing towards the growth of North America blood screening market.
Presence of leading product manufacturers, and increasing investment in product innovation is expected to drive the growth of blood screening market in North America. Asia Pacific is expected to be the fastest growing market during the forecast period. Expansion of healthcare infrastructure, spreading awareness regarding blood donation, and prevalence of infectious diseases are the key factors contributing towards the growth of Asia Pacific blood screening market.
The report titled “Blood Screening Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global blood screening market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Becton, Dickinson and Company reported revenues of USD 17.3 billion in 2019 and the product segment analysis of the company indicates that BD Medical business segment of the company dominated revenue in 2019.
The global blood screening market is segmented based on component, technology, end user, and geography. Based on component, the global blood screening market is segmented into reagents & kits, instruments, software, and services. Based on technology, the global blood screening market is segmented into nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), enzyme immunoassay (EIA), next-generation sequencing (NGS), western blotting, and others. Based on end user, the global blood screening market is segmented into blood banks, hospitals, and others. Based on geography, the global blood screening market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on blood screenings. Further, market share of prominent companies in the global blood screening market would also be estimated.
For instance, Becton, Dickinson and Company operates through three business segments namely BD Medical, BD Life Sciences, and BD Interventional. The Blood Screening products are delivered under BD Medical business segment of the company with revenue contribution of US$ 9.1 billion in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the blood screening reagent and product manufacturers. The global blood screening market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the blood screening business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global blood screening market.
Major players active in the global blood screening market include Abbott Laboratories, Beckman Coulter (Danaher Corporation), Becton Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Grifols, S.A., Ortho Clinical Diagnostics, Siemens, and Thermo Fisher Scientific.
Market Segmentation:
By Technology
By Product
By Geography:
Growing awareness regarding blood donation, increasing requirement of healthy blood form clinical applications, prevalence of infectious diseases, rising number of surgical procedures, and stringent regulations to monitor blood quality are the primary forces shaping the global blood screening market.
North America contributed the largest share to the global blood screening market in 2019 and is expected to witness prominent growth during the forecast period. Prevalence of infectious diseases, rising demand for healthy blood, and growth in volume of donated blood are the key factors contributing towards the growth of North America blood screening market.
Based on technology, the blood screening market is segmented into nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), enzyme immunoassay (EIA), next-generation sequencing (NGS), western blotting, and others.
The major active players are Abbott Laboratories, Beckman Coulter (Danaher Corporation), Becton Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Grifols, S.A., Ortho Clinical Diagnostics, Siemens, and Thermo Fisher Scientific.
The blood screening market is estimated to expand at a CAGR of 7.7% from 2023 to 2032.
The blood screening market was valued at US$ 2.3 billion in 2021.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved